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Abstract: Leishmaniasis is a neglected tropical disease affecting more than 12 million people
worldwide, which in its visceral clinical form (VL) is characterised by the accumulation of parasites in
the liver and spleen, and can lead to death if not treated. Available treatments are not well tolerated
due to severe adverse effects, need for parenteral administration and patient hospitalisation, and long
duration of expensive treatments. These treatment realities justify the search for new effective drugs,
repurposing existing licensed drugs towards safer and non-invasive cost-effective medicines for VL.
In this work, we provide proof of concept studies of butenafine and butenafine self-nanoemulsifying
drug delivery systems (B-SNEDDS) against Leishmania infantum. Liquid B-SNEDDS were optimised
using design of experiments, and then were spray-dried onto porous colloidal silica carriers
to produce solid-B-SNEDDS with enhanced flow properties and drug stability. Optimal liquid
B-SNEDDS consisted of Butenafine:Capryol 90:Peceol:Labrasol (3:49.5:24.2:23.3 w/w), which were then
sprayed-dried with Aerosil 200 with a final 1:2 (Aerosil:liquid B-SNEDDS w/w) ratio. Spray-dried
particles exhibited near-maximal drug loading, while maintaining excellent powder flow properties
(angle of repose <10◦) and sustained release in acidic gastrointestinal media. Solid-B-SNEDDS
demonstrated greater selectivity index against promastigotes and L. infantum-infected amastigotes
than butenafine alone. Developed oral solid nanomedicines enable the non-invasive and safe
administration of butenafine as a cost-effective and readily scalable repurposed medicine for VL.
Keywords: butenafine; SNEDDS; solid SNEDDS; spray drying; leishmaniasis; design of experiments
1. Introduction
Leishmaniasis is an infectious disease caused by parasites belonging to the Leishmania genus.
The prevalence of leishmaniasis exceeds 12 million cases, and it is endemic in 98 countries in five
continents. Leishmania parasites are transmitted by insect vectors from the genus Lutzomyia sp. or
Psychodopygus sp. in the New World and Phlebotomus sp. in the Old World [1,2]. Leishmaniasis presents
in the cutaneous (CL) and visceral (VL) leishmaniasis forms, depending on the type of host immune
response and infecting parasite species [3,4]. In the New World, parasites of the subgenus Vianna
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cause only CL and mucocutanoues leishmaniasis (MCL) while parasites of the subgenus Leishmania are
responsible for CL and VL [5]. VL is a chronic disease caused by L. (L.) infantum and L. (L.) donovani
species [6–8] residing in host macrophages, mainly from spleen, liver, bone marrow, and lymph
nodes, and is characterized by prolonged fever, hepatosplenomegaly, lymphadenopathy, anemia with
leukopenia, hypergammaglobulinemia and hypoalbuminemia, weight loss, edema, and a debilitating
state leading to weakening and ultimately death if untreated [6].
VL treatment mainstays involve pentavalent antimonials (SbV) and amphotericin B (AmB) as
the first line in the developing and developed world, respectively [9]. Although they are both highly
efficacious in vivo, SbV are linked to severe and frequent side effects, limiting their use [9], combined
with a high rate of clinical resistance [10]. AmB, on the other hand, has shown limited resistance, but its
clinical use is limited by the high cost, especially for safer lipidic formulations, such as Ambisome®,
thermal instability, and nephrotoxicity [11,12]. Miltefosine, the only oral VL licensed treatment
(licensed in 2003 in India), has several limitations as monotherapy, as its activity is highly dependent
on the clinical form of leishmaniasis and the parasite strain, and patients frequently experience
severe gastrointestinal disorders. In addition, it is teratogenic, and thus cannot be used in women
of child-bearing age [13,14]. Miltefosine has a long elimination half-life (seven days) and a narrow
therapeutic index, characteristics that limit the administered dose, which can lead to subtherapeutic
levels over several weeks, encouraging the emergence of resistance [12,14,15]. Indeed, resistance has
been reported in India (a country that alone accounts for 50% of the VL worldwide burden) and
France [12]. Thus, available medicines for VL are outdated, impractical, insufficiently efficacious, or
subject to resistance and unacceptable toxicities. Ideal treatments for VL should be able to possess
greater than 95% efficacy, be orally administered, be stable in a tropical environment, be affordable,
and require fewer than 11 days of treatment with an excellent side-effect profile [12,16].
Repurposing drugs is a strategy that has been crowned with success, as repurposed drugs have
made up a third of all new commercially and clinically used drug treatments since 2009 [17,18].
Current VL drugs are interesting examples of repurposed drugs, since SbV, AmB, and miltefosine were
originally used as an emetic, antifungal, and anticancer drug, respectively [14,19]. Butenafine is an
allylamine drug, commonly employed in the treatment of fungal skin infections, such as ringworm,
athlete’s foot, jock itch, and pityriasis. Currently, it is only commercialised as a 1% cream for topical
use. We have shown recent reports on how butenafine repositioning was effective in vitro against
L. (L.) amazonensis and L. (V.) braziliensis, ethiological agents of CL and MCL. Furthermore, parasite
treated with butenafine showed morphological alterations that resembled programmed cell death,
which is attributed to the blockage of the biosynthesis of ergosterol [20]. Butenafine has limited oral
bioavailability, with 1.5–3% of the oral dose being recovered in the plasma an hour after a single oral
dosing of radiolabeled butenafine (0.2 mg/kg) in rats [21]. Butenafine is highly metabolized in the liver
(methylation, dealkylation, and hydroxylation) and only 0.03% of the oral dose has been recovered
intact from the plasma after 4 h [21]. This concurs with levels of its major metabolite (1-napthoic acid)
in the plasma, which ranged between 1%–100% of administered parent drug dose [21].
Here, we are reporting the development of an oral butenafine nanomedicine able to enhance its
aqueous solubility, maintaining a solubilized state in the gastrointestinal to allow for enhanced oral
absorption, in order to target the liver and spleen (i.e., organs where the Leishmania parasite resides in
high concentration). We have shown that SNEDDS are able to enhance the oral bioavailability of poorly
soluble drugs and enable therapeutic concentrations to be delivered in the liver and spleen [12]. Thus,
we hypothesised that if butenafine is formulated with GRAS (Generally Regarded as Safe) excipients
with known activity against different Leishmania strains [22], we can develop butenafine-loaded
SNEDDS (B-SNEDDS) and solid SNEDDS (solid B-SNEDDS) with enhanced activity, as well as being
able to maintain butenafine’s oral solubilisation capacity in the gastrointestinal tract. To ensure that a
stable, and ideally solid, cost-effective formulation is available, we used design of experiments (DoE)
studies to prepare butenafine SNEDDS colloidal silicon dioxide spray-dried particles that can be easily
compressed into cost-effective, easily scalable, solid dosage forms of a repurposed drug for VL.
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2. Materials and Methods
2.1. Materials
Butenafine hydrochloride (purity ≥ 98%) was purchased from Cayman Chemical Co. (Michigan,
MI, USA). SNEDDS excipients (Capryol 90 (propylene glycol monocaprylate), Labrafil M 1944 CS
(oleoyl polyoxyl-6 glycerides), Labrasol (caprylocaproyl polyoxyl-8 glycerides), and Peceol (glyceryl
monooleate)) were kindly donated by Gattefosse (Saint-Priest Cedex, France). Two Aerosil silicon
dioxide excipients were used as inert solid carriers: Aerosil R972 from Degussa (Frankfurt, Germany)
and Aerosil 200 from Evonik Industries (Darmstadt, Germany). All other chemicals were of ACS
reagent grade (Sigma Aldrich, Madrid, Spain) and were used as supplied. Solvents were of HPLC
grade (Fisher, Madrid, Spain).
2.2. Solubility Studies of Butenafine
An excess quantity of butenafine was added to each of the excipients used in the preparation
of SNEDDS, and the mixture was shaken (300 rpm) overnight at 25 ◦C in triplicate. The mixtures
were centrifuged at 3000 rpm for 5 min, and the supernatant (0.1 mL) was diluted with 10 mL of
methanol. The absorbance was measured in a spectrophotometer (JASCO V-730 spectrophotometer
Madrid, Spain) at 220 nm to determine the solubility of butenafine. A calibration curve was performed
previously in methanol to establish the linearity between concentration and absorbance at 220 nm.
2.3. Pseudo-Ternary Phase Diagrams
Ternary phase diagrams were constructed to study the phase behaviour of oils/surfactants over
the whole concentration range. The existence of a microemulsion (type II) region within this diagram
was observed visually. A D-Optimal design was developed using different mixtures of Capryol 90,
Labrasol, and Peceol by using Design Expert software (State Ease, Minneapolis, MN, USA). Mixtures
were vortexed for 5 min. The particle size distribution (PSD) was measured after dilution in deionised
water (1:1000 v/v) in a Microtrac Zetatrac (Microtrac, Montgomeryville, PA, USA). The optimal excipient
combination leading to the smallest PSD upon dilution was selected, in order to solubilise the drug
and perform further experiments.
2.4. Preparation of Liquid B-SNEDDS Formulations
Based on solubility and phase diagram studies, Labrasol, Capryol 90, and Peceol were selected
as a high-hydrophilic-lipophilic balance (HLB) surfactant, a medium-HLB surfactant, and an oil,
respectively. Optimal SNEDDS were prepared combining the three as Capryol 90:Labrasol:Peceol
(51:24:25 w/w). Butenafine (30 mg/g) was solubilised in the resulting excipient mixture, which was
stirred overnight in order to obtain a homogenous isotropic mixture.
2.5. Preparation of Solid B-SNEDDS Formulation
A mini-spray dryer (Büchi B-191) was employed for the preparation of solid B-SNEDDS. Aerosil
200 (hydrophilic fumed amorphous silica, 5–50 nm (Evonik industries, Darmstadt, Germany)) or
Aerosil R972 (hydrophobic fumed amorphous silica, 16 nm (Degussa AG, Frankfurt, Germany))
were used as inert carriers. A carrier (1 g) was dispersed in 100 mL of ethanol by magnetic stirring,
after which liquid B-SNEDDS formulation (0.5 g) was mixed. The resulting suspension was delivered
to a two-fluid nozzle (0.7 mm nozzle tip and a 1.5 mm diameter nozzle screw cap) using a peristaltic
pump, at a speed of 10% (5 mL/min). Compressed air (2 bars) was used as the drying gas in a co-current
mode, with the aspirator capacity set to maximum (100%). The flow-meter for the standard two-fluid
nozzle was set to 600 NL/h. The inlet temperature was fixed at 62 ◦C, and the outlet temperature varied
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between 32 and 36 ◦C. After spray-drying, the dry powder was collected from the collector vessel,
and the yield of the process was quantified using the following equation:
Yield (%) =
Collected mass a f ter spray drying (mg)
Total mass spray dried (mg)
× 100 (1)
A 22 DoE was performed to understand and optimise key formulation parameters affecting
the preparation of solid B-SNEDDS. The surface properties of silica used, i.e., type of Aerosil (200
or R972), as well as the weight ratio between Aerosil and liquid B-SNEDD (1:2 or 1:3 w/w) on the
physicochemical properties of the spray-dried product were investigated. Five different responses
were studied: (i) powder flow, (ii) yield, (iii) drug loading, (iv) particle size upon dilution (1:1000 w/w),
and (v) the percentage of drug release at 60 min in simulated gastric fluid (500 mL buffer solution of
pH 1.2).
2.6. Characterisation of the Solid B-SNEDDS
2.6.1. Powder Flow: Angle of Repose (AoR) Measurements
The angle of repose (AoR) was determined according to the United State Pharmacopeia (<1174>
Powder Flow) by using the fixed height funnel method (i.e., by measuring the cone height versus
the base, formed by the powder falling through a plastic funnel placed 10 cm from the table surface
until a stable cone was formed) [23]. AoR measurements were carried out by passing 500 mg of solid
B-SNEDD in triplicate. After the powder was deposited on the surface, the height of the powder cone
(h) and the radius of the base (r) were measured. The inclination of the cone created between the
powder and the surface (α, AoR) was calculated using the following equation:
tan(α) =
h
r
(2)
2.6.2. Particle Size Measurements
The particle size of both liquid B-SNEDDS and solid B-SNEDDS were determined at 25 ◦C after
1:1000 w/w dilution in deionised water. Solid B-SNEDDS were centrifuged (9000 rpm, 5 min) prior
to measurements, in order to precipitate the insoluble carrier. The mean size (n = 3) by volume (nm)
was measured using a Microtrac Zetatrac (Microtac Inc., Montgomeryville, PA, USA), with an internal
probe ranging from 0.0008 to 6.5 µm [24].
2.6.3. Release Studies
Release studies of solid B-SNEDDS (500 mg) containing 10 mg of butenafine were performed
at 37 ◦C for 1 h in simulated gastric fluid (SGF; 500 mL buffer solution of pH 1.2), followed by a
second consecutive hour in simulated intestinal fluid (SIF; 400 mL buffer solution of pH 6.8) in a
calibrated dissolution apparatus (Erweka type DT80, Erweka, Heusenstamm, Germany). The SGF
and SIF were prepared as described in the USP [25]. Based on predicted water solubility values
(7.5 × 10−5 mg/mL, according to the Drug Bank Database [26]), release studies were performed in
non-sink conditions, with the aim of testing a relevant pharmacological drug dose (10 mg). At different
time points (5, 10, 15, 30, 45, 60, 90, and 120 min), a 2 mL sample was withdrawn, filtered through a
Millipore Millex PTFE membrane filter (0.45 µm), diluted 1:2 with acetonitrile, and injected in the HPLC.
Butenafine concentration was quantified using an HPLC equipped with a Jasco PU-1580 pump, a Jasco
AS-2050 Plus autosampler, and a Jasco UV-1575 UV-visible detector. Integration of the peaks was
performed using the Borwin 1.5 software. Butenafine was separated on an Agilent Eclipse XDB-Phenyl
reverse-phase column (250 mm × 4.6 mm, 5 µm). The mobile phase consisting of methanol/water
(78:22 v/v) was pumped at 1.4 mL/min, and a sample injection volume of 20 µL was used. The column
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temperature was kept at 25 ◦C, and the detector was set at 220 nm. Butenafine concentrations were
calculated from a linear regression calibration curve between 100.0–0.1 µg/mL.
2.6.4. Drug Loading
Solid B-SNEDD formulations (10 mg) were dissolved in 0.5 mL of dimethyl sulfoxide (DMSO),
vortexed for 5 min, and then diluted in acetonitrile (1:40 v/v) prior to drug quantification by the
above-described HPLC method.
2.6.5. Morphological Analysis
The morphology of solid B-SNEDDS was examined using a scanning electron microscope (JEOL
JSM 6335F Ltd., Akishima, Japan) at 5 kV. The samples were fixed on a brass stub using double-sided
adhesive tape, and vacuum-coated with gold (Au) for 180 s (coater: Q150R S, Quorum, Lewes,
East Sussex, United Kingdom).
2.6.6. Tabletting and Hardness
In order to investigate the compression of the solid B-SNEDDS without the addition of any other
excipient, solid B-SNEDDS (500 mg) were compressed using a Perkin Elmer hydraulic press (Waltham,
MA, USA) and a 13 mm punch, and die set under different pressures of 0.5, 1.0, 3.0 or 5.0 tonnes for
15 s. Hardness was undertaken according to the European Pharmacopeia [27], using a Pharma Test
PTB 311 instrument (Pharma Test, Hainburg, Germany). Tablets (n = 3) were individually evaluated,
and the mean value of the force in Newtons (N) was reported.
2.7. In Vitro Efficacy and Toxicity Studies
2.7.1. Parasites and Cell Lines
The parasites were kindly provided by Prof. Dr. Fernando Tobias Silveira from the cryobank of the
Leishmaniasis Laboratory of Prof. Dr. Ralph Laison, Department of Parasitology, Ministry of Health,
Evandro Chagas Institute (Belem, Para, Brazil). They were identified using monoclonal antibodies and
isoenzyme electrophoretic profiles at the Leishmaniasis Laboratory of the Evandro Chagas Institute.
The Leishmania species used was L. (L.) infantum (MHOM/BR/72/46). Parasites in a late log stage were
used for all experiments. Parasites were maintained in Schneider’s Medium (SigmaAldrich, Madrid,
Spain), supplemented with 10% heat-inactivated fetal bovine serum, 50,000 IU/mL penicillin, and 50
µg/mL streptomycin.
BALB/c mice, 6 weeks old, were obtained from the Medical School of the University of
São Paulo, Brazil, in order to collect peritoneal macrophages to perform the in vitro test against
intracellular Leishmania amastigotes. To obtain the macrophages, the animals were anaesthetized with
thiopental (1 mg/200 mL) and euthanized. This study was carried out in strict accordance with the
recommendations detailed in the Guide for the Care and Use of Laboratory Animals of the Brazilian
National Council of Animal Experimentation (http://www.cobea.org.br). The protocol was approved
by the Ethics Committee of Animal Experiments of the Institutional Committee of Animal Care and
Use at the Medical School of Sao Paulo University (CEUA-FMUSP number 098/17).
2.7.2. In Vitro Promastigote Efficacy and Cytotoxicity
Promastigote forms of L. (L.) infantum (2 × 107 promastigotes/well) were incubated in a 96-well
culture plate in RPMI 1640 medium, with pH 4.2 and drugs in a range of 0.01 to 400 µM. The negative
control group was cultivated in medium and vehicle solution (PBS plus 1% DMSO). The parasites
were incubated for 48 h at 25 ◦C, and washed with 200 µL of sodium chloride 0.9% (w/v) three
times with centrifugation at 3000 rpm for 10 min at 4 ◦C, followed by the addition of MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (9.6 µM). Four hours later, 50 µL
of 10% sodium dodecyl sulphate (SDS) was added to each well. The plates were further incubated
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for 18 h and read in an ELISA reader (Labsystems Uniscience Multiskan EX, Miami, FL, USA) at 595
nm. Effective concentration 50% (EC50) was estimated using Graph Pad Prism 5.0 software (GraphPad
Software, San Diego, CA, USA).
Approximately 5 × 105 peritoneal macrophages from BALB/c mice were cultured in RPMI 1640
medium, with the drugs in a range of 0.01 to 400 µM, in 96-well plates. As a negative control,
macrophages were cultivated with vehicle solution. After 48 h, cell viability was analysed by the MTT
method. Cytotoxic concentration 50% (CC50) was estimated with Graph Pad Prism 5.0 software.
The selectivity indexes (SI) were calculated using the ratio CC50/EC50 toward promastigote (SIp)
or amastigote (SIa) forms. EC50 represents the concentration of the formulation that produced a 50%
reduction in parasites, while CC50, represents the concentration of the formulation that produced a
50% reduction of cell viability in treated culture cells with respect to untreated ones.
2.7.3. Macrophage Infection and Treatments
Peritoneal macrophages from BALB/c mice (5 × 105 macrophages) were cultivated in round
cover slips in a 24-well plate, followed by infection with L. (L.) infantum promastigotes at a ratio of
10 parasites per 1 peritoneal macrophage. Plates were incubated at 5% CO2 at 37 ◦C. After 24 h of the
initial infection, drugs were added at 25, 50, or 100 µM. Round cover slips from each experimental
time point were dried at room temperature, fixed in methanol, and stained by Giemsa 5% (two drops).
The infection index (II) was then estimated according to Passero et al. [28], using the following equation:
II = % in f ected macrophages × Internalized amastigotes
Macrophages
(3)
2.8. Statistical Analysis
Statistical analyses were performed via a one-way ANOVA test using Minitab 15 (Minitab Ltd.,
Coventry, UK), followed by Tukey’s test. Statistical significance was set at p < 0.05. Data was plotted
using Origin X9 (Northampton, UK).
3. Results
3.1. Solubility Studies of Butenafine
The solubility of butenafine was tested in four different excipients (Peceol, Capryol 90, Labrasol,
and Labrafil M1944CS) that are commonly utilized in the development of lipid-based formulations
and have been shown to possess efficacy against leishmaniasis [22] (Table 1). Butenafine was more
soluble in excipients with oleic acid lipids or triglycerides, i.e., Peceol and Labrafil M 1944 CS, followed
by lower HLB excipients such as Capryol 90. Due to the low miscibility between Peceol and Labrafil,
and the higher butenafine solubility in Peceol, Peceol was chosen as the oil phase to be combined with
Capryol and Labrasol for the pseudo-ternary diagram and identification of the optimal composition
(Table 2) able to yield microemulsions (type II) upon aqueous dilutions.
Table 1. Solubility of butenafine in various vehicles at 25 ◦C (n = 3).
Vehicle Butenafine (mg/g) HLB *
Peceol 24.68 ± 0.21 1
Capryol 90 15.79 ± 1.18 5
Labrasol 13.03 ± 3.94 12
Labrafil M 1944 CS 22.59 ± 1.66 9
* Hydrophilic-lipophilic balance of the vehicles; values obtained from Gatefosse website [29].
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Table 2. Design of experiments (DoE) of liquid butenafine self-nanoemulsifying drug delivery systems
(B-SNEDDS). Excipient quantities are expressed as a fraction, considering that the sum of all excipients
was equal to 1 g. For each combination, the average particle size (n = 3) in numbers after dilution in
de-ionised water (1:1000 w/w) was illustrated.
Experiment Labrasol Capryol 90 Peceol Particle Size (nm)
1 0.29 0.50 0.2 116
2 0 0.50 0.49 376
3 0 0.8 0.2 289
4 0.19 0.2 0.60 191
5 0.22 0.41 0.35 156
6 0.29 0.50 0.2 178
7 0.09 0.61 0.29 244
8 0 0.2 0.8 1735
9 0 0.50 0.49 410
10 0.39 0.34 0.26 107
11 0.4 0.2 0.4 101
12 0.12 0.35 0.52 167
13 0 0.2 0.8 1340
14 0 0.34 0.65 1180
15 0 0.8 0.2 352
16 0.19 0.2 0.60 141
3.2. Pseudo-Ternary Phase Diagrams and Preparation of Liquid B-SNEDDS Formulations
A ternary phase diagram (Table 2 and Figure 1) was constructed to study the phase behaviour of
oil/surfactants over the whole concentration range. Particle size expressed in numbers led to a better
predictive model with a higher R2 than the one using values expressed in volume. The blue region
indicates the self-nanoemulsifying region, with a lower particle size. The particle size optimisation
studies suggested two optimal excipient combinations with the following composition:
(1) Combination A: Peceol:Capryol:Labrasol mixed at 27:58:15 w/w
(2) Combination B: Peceol:Capryol:Labrasol mixed at 25:51:24 w/wPharmaceutics 2019, 11, x 8 of 15 
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size of each corresponding composition. The blue areas indicate a lower particle size, while yellow and
red areas indicate larger sizes.
Pharmaceutics 2019, 11, 353 8 of 14
Validation studies were performed by preparing the suggested optimal mixtures, followed by
measuring the particle size. The resulted particle size was 159.7 nm for combination A, and 88.4 nm
for combination B. Based on these results, combination B was selected for further development of
solid-B-SNEDD formulations.
3.3. Yield of Solid B-SNEDDS
Four different solid B-SNEDDS were manufactured utilising the vehicle mixture (combination
B) above described. Two different hydrophobic, fumed silica carriers (Aerosil 200 or R972) were
combined in two ratios (1:2 and 1:3 w/w), with the optimised liquid B-SNEDDS and the resulting four
formulations coded as F1 to F4, respectively (Table 3). When SNEDDS were adsorbed on Aerosil 200
at a 1:2 ratio (F1), a higher yield was obtained, which was able to carry higher amounts of liquid
B-SNEDDS (1:3 ratio). Hydrophobic fumed silica resulted in a poorer yield, indicating that SNEDDS
adsorbed easier towards a hydrophilic surface, suggesting a core shell particle structure for liquid
B-SNEDDS, with Labrasol being orientated towards the surface, and likely to interact more strongly
with hydrophilic silica surfaces. However, this stronger interaction of labrasol with hydrophilic silicas
has been linked previously to poorer disintegration times, which should be taken into account later
when manufacturing solid dosage forms, such as tablets [30].
Table 3. Characterisation of the solid B-SNEDDS. Results are reported as mean ± SD (n = 3).
Code AerosilType
Carrier:
B-SNEDDS
Ratio (w/w)
Yield (%) Angle ofRepose (◦)
Drug
Loading
(%)
Particle
Size (nm)
Butenafine
Released at 60
min in SGF (%)
F1 200 1:2 71.1 ± 1.6 19.1 ± 5.4 94.1 ± 0.1 119.8 ± 2.3 45 ± 2.0
F2 200 1:3 66.5 ±10.2 15.9 ± 3.0 96.5 ± 2.4 25.9 ± 1.2 28 ± 5.0
F3 R972 1:2 32.9 ± 1.3 20.6 ± 0.2 85.5 ± 4.6 279 ± 8.7 18 ± 4.0
F4 R972 1:3 47.4 ± 22.6 8.7 ± 1.5 97.0 ± 2.1 1 * 20 ± 0.2
* Particle size measurements of F4 were registered as 1 nm, indicating that particles were not stable upon dilution.
All solid B-SNEDDS had an AoR below 20◦, indicative of excellent flow properties [31,32] with near
maximal drug loading (Table 3). Particle size measurements confirmed microemulsion regions with a
size well below 300 nm. F4 yielded particles that either had not been able to re-form after adsorption
on silica, or were unstable after the 1:1000 dilution, and thus were considered not appropriate for
further development.
3.4. Release Studies
Hydrophilic fumed silica particles indicated a greater and faster release of butenafine
nanoemulsions type II (F1 > F2 > F3~F4) (Figure 2). Increasing the pH from 1.2 to 6.8 to mimic the
intestinal pH resulted in a sharp precipitation, which can be linked with a spring–parachute effect.
This can explain the low absorption of butenafine orally [21], as that only allows for absorption in the
upper part of the gastrointestinal tract [33,34]. Butenafine is more soluble in acidic pH as a hydrochloride
salt, while its base (pKa: 9.23) has limited water solubility (<100 ng/mL) [35]. Formulation F1 allows
for higher solubilised levels up to 90 min (p < 0.05; one-way ANOVA), which is critical for enhancing
oral absorption.
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3.5. Morphological Analysis
The morphology of the four solid B-SNEDDS formulations was observed by scanning electron
microscopy (Figure 3). At higher magnification, the large surface porosity of both silicon dioxide
carriers can be observed. This explains the high amount of liquid SNEDDS that is able to be adsorbed
on to the solid carriers, up to three times their own weight. However, agglomeration between carrier
particles was more noticeable in those formulations containing a higher ratio of liquid SNEDDS (F2
and F4), which can explain the hindered release observed. In the F3 and F4, both containing the most
hydrophobic carrier (Aerosil R972), it was observed that even at the lower ratio of liquid-SNEDDS (1:2
w:w), the aggregation between particles is still evident to some extent.
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Figure 3. Scanning electron microscope (SEM) micrographs of solid B-SNEDDS F1, F2, F3, and F4
formulations at two different magnifications.
3.6. Tableting and Hardness
Amongst all the solid B-SNEDDS, only the F1 formulation was able to be compacted with adequate
hardness without the incorporation of other excipients. We should bear in mind that the addition of
other excipients will further dilute the butenafine dose per tablet size, which currently is 10 mg/500 mg
tablet in powder form (Table 4). The addition of microcrystalline cellulose is likely to allow other solid
SNEDDS to be formulated with appropriate hardness.
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Table 4. Hardness of the F1 solid B-SNEDDS formulation. Hardness expressed as minimum and
maximum values.
Compaction Pressure (kN) Hardness (N) Dimension (mm)
9806.65 15.6–18.4 12.91 × 3.17
19,613.3 7.7–20.1 12.91 × 3.17
3.7. In Vitro Efficacy and Cytotoxicity
Miltefosine was active against both promastigote and amastigote forms of L. (L.) infantum,
exhibiting an EC50 of 17.9 ± 0.9 and 13.7 ± 0.7µM, respectively, as well as a mild cytotoxicity (CC50 of
126.3 ± 3.5 µM) leading to a selectivity index towards promastigotes forms (SIp) of 7.0 and a selectivity
index towards amastigotes forms (SIa) of 9.2 (Table 5). These values are similar to previous documented
studies [36]. Free butenafine showed lower efficacy than miltefosine (Table 5), with an SI close to
the unit indicating poor selectivity for the parasites over the macrophages. Amongst the four solid
B-SNEDDS, F1 and F4 showed better efficacy against promastigotes (p < 0.05), while Aerosil R972
formulations (F3 and F4) demonstrated lower cytotoxicity and higher efficacy against amastigotes
(p < 0.05), but whether this is driven by the excipient is not clear, and further studies are needed. In any
case, except for F2, formulating butenafine as SNEDDS has improved its selectivity index, making it
less toxic and more active than the free drug.
Table 5. Antileishmanial activity of solid B-SNEDDS formulations and butenafine were assayed against
promastigote and amastigote forms of L. (L.) infantum. Cytotoxicity was analysed using peritoneal
macrophages from BALB/c mice. EC50 represents the concentration of the formulation that produced a
50% reduction in parasites, while CC50 represents the concentration of the formulation that produced a
50% reduction of cell viability in treated culture cells with respect to untreated ones. SIp: selectivity
index towards promastigotes forms; SIa: selectivity index towards amastigotes forms.
Formulation EC50 (µM)Promastigote
CC50 (µM)
Macrophage
EC50 (µM)
Amastigote SIp SIa
F1 76.5 ± 3.0 * 225.8 ± 3.2 164.4 ± 3.4 2.9 1.3
F2 93.1 ± 3.0 127.2 ± 3.0 702.5 ± 3.2 1.3 0.1
F3 101.7 ± 3.2 ≥300.0 86.4 ± 2.9 * ≥3.0 ≥3.6
F4 73.9 ± 3.2 * 233.1 ± 3.0 27.0 ± 3.4 * 3.1 8.6
Butenafine 99.8 ± 3.1 109.3 ± 3.5 118.4 ± 3.6 1.0 0.9
Miltefosine 17.9 ± 0.9 126.3 ± 3.5 13.7 ± 0.7 7.0 9.2
* p ≤ 0.05 compared to Butenafine.
4. Discussion
Butenafine, a benzylamine derivative structurally similar to terbinafine, possesses antifungal
activity, attributed to its ability to directly cause damage on fungal cell membranes by disrupting
the early stages of ergosterol biosynthesis via inhibition of the enzyme squalene epoxidase [37].
This enzyme converts squalene to lanosterol, and leads to the accumulation of squalene [38]. Inhibition
of squalene epoxidase suppresses the biosynthesis of ergosterol, an essential lipid of fungal and
Leishmania cell membranes [39].
Therefore, butenafine is known for its antifungal effects in infections caused by Tinea pedis,
Tinea corporis, and Tinea cruris [40]. We have recently demonstrated the leishmanicidal effect of butenafine
against promastigote and amastigote forms of L. (L.) amazonensis and L. (V.) braziliensis [20]. Considering
the difficulties related to the treatment of leishmaniasis, such as drug relapses, toxicity, hospitalization,
and parenteral administration, the development of an oral, safe, multispecies, and effective medicament
could revolutionise VL treatment. Butenafine is a multispecies drug, able to be effective against a
range of parasite strains, such as L. (L.) amazonensis, L. (V.) braziliensis, and now in this work, it has
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been demonstrated that is also active against L infantum. However, due to its poor water solubility and
precipitation in the gastrointestinal tract, no oral formulations of butenafine have been licensed.
In order to pave the way for the market of oral medicines against VL, the selection of excipients
that can promote oral bioavailability and safety, as well as elicit a synergistic effect against Leishmania
parasites without compromising safety is critical. Peceol, Labrasol, and Capryol 90 have been selected
as GRAS excipients to formulate butenafine SNEDDS, able to enhance the drug solubilisation capacity
in the gastrointestinal tract and oral bioavailability [41]. Also, due to the proven efficacy of those
selected excipients against several strains of Leishmania parasites, a synergistic effect with butenafine
can be expected [22].
Pre-formulation studies have indicated that butenafine is more soluble in C18 lipids and
amphiphiles, and these were thus selected for forming the oil component of SNEDDS (Peceol).
We decided to combine these with the medium, as well as short chain fatty acids esters (Capryol 90)
and triglycerides (Labrasol) that we have recently shown to possess antileishmanial activity. The high
reported activity of lauric acid and labrasol against Leishmania parasites can be attributed to their
ability to selectively permeate the cell membrane of parasites, resulting in rapid and considerable
membrane damage and the loss of cellular potassium and magnesium [22]. SNEDDS were optimised
towards a minimised droplet particle size (~100 nm) for several reasons. Nanoemulsions (type II
microemulsions) are more stable than microemulsions, in terms of droplet flocculation and coalescence
(Ostwald ripening) [42]. The smaller the particle size, the higher the permeability across the intestinal
mucus brush border layer and cell membranes [43]. Additionally, small droplet sizes (~90 nm) provide
a large interfacial surface area for drug release and absorption across the intestinal cells [44]. Recent
reports suggest that a particle size between 100–500 nm is optimal for lymphatic uptake via the
gastrointestinal lymphatic system, but at a slower rate than particles sized 50–100 nm [45,46].
In order to reduce costs, increase the chemical stability, and improve patient compliance, B-SNEDDS
was transformed into a solid free-flowing powder by spray-drying, which can be directly compressed.
Fumed amorphous silica (Aerosil) are known to possess enhanced surface area for adsorption (Aerosil
200: 200 ± 25 m2/g and Aerosil R972: 110 ± 20 m2/g). Both silicas were able to adsorb three times their
own weight in SNEDDS, resulting in powders with excellent flow properties, as indicated by AoR
studies (<20◦) [30]. The higher porosity and hydrophilic surface of Aerosil 200 carriers explain the
higher drug release and yield, respectively. Loading was higher with Aerosil 200, which indicates a
core-shell morphology of the SNEDDS droplet, with polyethylene glycol chains stabilising the droplet
surface and enabling higher interactions with the hydrophilic surface of the silica [47,48]. Aerosil R972
carriers hinder the release of butenafine, possibly due to stronger hydrophobic interactions; however,
this is likely to limit oral bioavailability. Additionally, particles prepared with Aerosil R972, with high
SNEDDS loading when dispersed in water, are unable to yield an emulsion, indicating that droplets
are not able to re-form or are unable to maintain their morphology, and become unstable after a 1:1000
dilution. The latter, combined with limited release from these solid B-SNEDDS, makes them less likely to
be able to enhance oral bioavailability. Interestingly, though, these particles have a significantly impact
on the in vitro efficacy against Leishmania promastigotes and amastigotes. Even though butenafine
release from F3 and F4 formulations was low at physiological pH, these formulations possessed
enhanced efficacy and selectivity, with no higher cytotoxicity on macrophages. Enhanced surface
hydrophobicity can trigger macrophage uptake compared to particles with a hydrophilic surface [49].
However, when the results are taken together, formulation F1 is more likely to be a promising solid
nanomedicine for VL, as it maintains characteristics for enhanced solubilisation and oral uptake, as
well as presented antileishmanial activity in L. (L.) infantum promastigotes and amastigotes.
Limited studies are available in the literature for understanding the ability of solid carriers to
load SNEDDS. Preparing a conventional solid dosage form of SNEDDS remains challenging, as tablets
can be friable if a low compression force is used, or allow for SNEDDS leakage if a high compression
force is used. Tablets prepared with Labrasol and silica (Neusilin US2, a synthetic, amorphous form of
magnesium aluminometasilicate) have demonstrated an enhanced disintegration time and the need
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for a disintegrant [32]. Our solid B-SNEDDS were able to load high SNEDDS quantities, while being
free-flowing and easily compacted into the appropriate hardness tablets. Smith et al. [12] have
demonstrated that liquid SNEDDS can be transformed into solid tablets with good release properties
when the ratio between liquid to solid was 1:3. In our work, we have shown that even a much greater
ratio of liquid to solid (2:1) can still be compacted without SNEDDS leakage and maintain a homogenous
matrix for compaction. However, further studies are required to investigate the manufacturing of these
free-flowing powders into tablets that meet the USP Pharmacopeia requirements.
5. Conclusions
Manufacturing of cost-effective solid dosage forms of reformulated drugs is an ideal strategy
to speed up the development of novel medicines for VL and other neglected diseases. We have
demonstrated for the first time the efficacy of butenafine for VL, while developing an easily scalable
preparation from GRAS excipients of solid dosage forms of butenafine, able to maintain its solubilisation
capacity in the gastrointestinal tract. SNEDDS were optimised for drug loading (30 mg/g) and particle
size, and we have demonstrated the ability of a microemulsion to be formed after release from fumed
silica particles. Solid SNEDDS demonstrated excellent flow properties, and were able to be compressed
in adequate hardness tablets. They also demonstrated antileishmanial activity in L. (L.) infantum
promastigotes and amastigotes, which indicated their potential as solid nanomedicines for the treatment
of VL.
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